Fiona Dunbar
Chief Medical Advisor at Beckley Psytech
Data updated
Research Footprint
Fiona Dunbar appears in 7 tracked papers (2021–2026), most studied alongside 5-MeO-DMT, Placebo and Psilocybin, across Safety & Risk Management, Chronic Pain and Depressive Disorders.
Most-cited paper: A narrative synthesis of research with 5-MeO-DMT (81 citations).
Frequent co-authors: Mathieu Seynaeve, Anna Ermakova and James Rucker.
Background & Research
Fiona Dunbar is a Pharmaceutical Physician who serves as Chief Medical Advisor at Beckley Psytech. Before joining Beckley Psytech, she spent 29 years at Janssen (Johnson & Johnson), where she held increasing responsibilities in Research & Development and Medical Affairs and contributed to development programs across neuroscience, immunology, oncology, and infectious diseases. She also has a background as a Medical Officer at the South African Institute of Medical Research and holds an MB BCh from the University of the Witwatersrand.
Key Impact
She is a medical leader helping advance clinical development of 5-MeO-DMT/BPL-003 for psychiatric and addiction indications, including depression and alcohol use disorder.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Fiona Dunbar is associated with.
Beckley Psytech
Private BiotechBeckley Psytech was a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the Beckley Foundation — the UK-based psychedelic research charity co-founded by Amanda Feilding. The company focused on developing novel proprietary psychedelic formulations, with its lead asset BPL-003, an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) for treatment-resistant depression. BPL-003 received FDA Breakthrough Therapy Designation and delivered positive Phase 2b results. In November 2025, Beckley Psytech merged with atai Life Sciences in an all-share transaction to form AtaiBeckley, with BPL-003 becoming the lead asset of the combined company.
View stakeholder →Janssen Research & Development
pharmaJanssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
View stakeholder →King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →